Edition:
United Kingdom

Cambrex Corp (CBM.N)

CBM.N on New York Stock Exchange

40.18USD
4:21pm GMT
Change (% chg)

$0.28 (+0.70%)
Prev Close
$39.90
Open
$40.00
Day's High
$40.34
Day's Low
$39.90
Volume
11,199
Avg. Vol
90,629
52-wk High
$69.40
52-wk Low
$39.40

Latest Key Developments (Source: Significant Developments)

Cambrex To Acquire Avista Pharma Solutions
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Cambrex Corp ::CAMBREX TO ACQUIRE AVISTA PHARMA SOLUTIONS, ADDING EARLY STAGE API AND FINISHED DOSAGE FORM DEVELOPMENT & TESTING SERVICES TO ITS GLOBAL CONTRACT DEVELOPMENT & MANUFACTURING NETWORK.CAMBREX CORP - DEAL FOR APPROXIMATELY $252 MILLION.CAMBREX CORP - DEAL FOR APPROXIMATELY $252 MILLION..CAMBREX CORP - CAMBREX EXPECTS TRANSACTION TO BE ACCRETIVE TO ADJUSTED EARNINGS PER SHARE IN 2019..CAMBREX CORP - POST DEAL, NET LEVERAGE RATIO, PRO FORMA FOR DEAL, EXPECTED TO BE ABOUT 2.4 TIMES EBITDA.CAMBREX CORP - AVISTA'S 330 PERSON WORKFORCE WILL JOIN CAMBREX'S 1,700 EMPLOYEES ACROSS UNITED STATES AND EUROPE.CAMBREX CORP - HAS SECURED COMMITTED FINANCING FOR PROPOSED INCREASE.CAMBREX - DEAL IS EXPECTED TO BE FUNDED WITH COMBINATION OF CASH & BORROWINGS UNDER CO'S EXISTING REVOLVING CREDIT FACILITY.CAMBREX CORP - CAMBREX'S EXISTING REVOLVING CREDIT FACILITY WILL BE INCREASED THROUGH ACCORDION FEATURE.  Full Article

Cambrex Reports Second Quarter 2018 Results
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Cambrex Corp ::CAMBREX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $0.87 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.Q2 GAAP EARNINGS PER SHARE $1.21 FROM CONTINUING OPERATIONS.Q2 EARNINGS PER SHARE VIEW $0.66 -- THOMSON REUTERS I/B/E/S.Q2 REVENUE $152 MILLION VERSUS I/B/E/S VIEW $136 MILLION.2018 FULL YEAR ADJUSTED NET REVENUE GROWTH AND ADJUSTED EBITDA GUIDANCE REAFFIRMED.SEES FULL YEAR 2018 ADJUSTED INCOME FROM CONTINUING OPERATIONS PER SHARE $2.91 - $3.14.  Full Article

Cambrex To Acquire Halo Pharma
Monday, 23 Jul 2018 

July 23 (Reuters) - Cambrex Corp ::CAMBREX TO ACQUIRE HALO PHARMA, ADDING DRUG DEVELOPMENT AND FINISHED DOSAGE CAPABILITIES TO GLOBAL API MANUFACTURING NETWORK.CAMBREX CORP - DEAL FOR APPROXIMATELY $425 MILLION.CAMBREX CORP - WILL ACQUIRE HALO FOR $425 MILLION IN TOTAL CASH CONSIDERATION.CAMBREX CORP - EXPECTS TRANSACTION TO BE ACCRETIVE IN 2019.CAMBREX CORP - ACQUISITION WILL BE FUNDED WITH A COMBINATION OF CASH ON HAND AND BORROWINGS AGAINST CAMBREX'S $500 MILLION SENIOR CREDIT FACILITY.  Full Article

Cambrex Announces Investment At Its Charles City, Iowa Plant
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Cambrex Corp ::CAMBREX CORP - ANNOUNCED AN INVESTMENT TO EXPAND CHEMICAL AND ANALYTICAL DEVELOPMENT CAPABILITIES AT ITS CHARLES CITY, IOWA PLANT.CAMBREX CORP - CHARLES CITY, IOWA PLANT EXPANSION WILL SEE CONSTRUCTION OF AN ADDITIONAL 2,000 SQ.FT. OF LABORATORY SPACE FOR DEVELOPMENT PROJECTS.  Full Article

Cambrex reports Q3 adjusted earnings per share $0.55 from continuing operations
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cambrex Corp :Cambrex reports third quarter 2017 financial results.Q3 adjusted earnings per share $0.55 from continuing operations.Q3 gaap earnings per share $0.52 from continuing operations.Q3 earnings per share view $0.48 -- Thomson Reuters I/B/E/S.Sees fY 2017 revenue up 7 to 11 percent.Q3 revenue $112.6 million versus I/B/E/S view $107.4 million.Cambrex Corp - ‍2017 full year financial guidance reaffirmed​.  Full Article

Cambrex appoints Gregory Brown to its board of directors
Friday, 3 Nov 2017 

Nov 3 (Reuters) - Cambrex Corp :Gregory B. Brown M.D. Appointed to the board of directors of Cambrex corporation.Cambrex Corp - ‍brown's appointment increases size of board to ten members​.  Full Article